High PSA Values and Previous Negative Biopsy Results: A Randomized Controlled Trial Active Surveillance Candidate for active Canadian Unknown September NCT01354171 250 1 year III-2 Magnetic Resonance surveillance Urology – status 2014 Population 2 Imaging Study (ASIST) Research has not Canada Consortium been verified in more than two years NCT02053805 Personalized Prostate Male carrier of mutation in Rabin Medical 200 2 years Recruiting June 2018 III-3, Cancer Screening Among BRCA 1\2 or germ-line Center diagnostic Population 1 Men With High Risk mutations in the MMR case-control Israel Genetic Predisposition- a genes (MLH1, MSH2 , study, Prospective Cohort Study MSH6 or PMS2) screening population Multi-parametric MRI in Aarhus February III-3, NCT02326246 Men with low-risk PCa 60 1 year Recruiting the Diagnosis and University 2017 diagnostic Population 2 Surveillance of Low-risk Hospital Skejby case-control Denmark Prostate Cancer study NR = not reported, PCa = prostate cancer, MRI = magnetic resonance imaging, RCT = randomised controlled trial, mpMRI = Multiparametric MRI.
High PSA Values and Previous Negative Biopsy Results: A Randomized Controlled Trial NCT01354171 Population 2 Canada Active Surveillance Magnetic Resonance Imaging Study (ASIST) Candidate for active surveillance Canadian Urology Research Consortium 250 1 year Unknown – status has not been verified in more than two years September 2014 III-2 NCT02053805 Population 1 Israel Personalized Prostate Cancer Screening Among Men With High Risk Genetic Predisposition- a Prospective Cohort Study Male carrier of mutation in BRCA 1\2 or germ-line mutations in the MMR genes (MLH1, MSH2 , MSH6 or PMS2) Rabin Medical Center 200 2 years Recruiting June 2018 III-3, diagnostic case-control study, screening population NCT02326246 Population 2 Denmark Multi-parametric MRI in the Diagnosis and Surveillance of Low-risk Prostate Cancer Men with low-risk PCa Aarhus University Hospital Skejby 60 1 year Recruiting February 2017 III-3, diagnostic case-control study NR = not reported, PCa = prostate cancer, MRI = magnetic resonance imaging, RCT = randomised controlled trial, mpMRI = Multiparametric MRI.
1397_Final_MSAC_Assessment_Report.docx